Berkeley Lab startup Newomics, founded on the multinozzle emitter array (MEA) technology invented at Berkeley Lab, continues to grow. According to the announcement:
Daojing Wang, Ph.D., Newomics’ founder and CEO, says the proceeds will be used to launch new products, grow the sales and marketing team, enhance customer support, and expand the collaborations with prominent mass spectrometer vendors. Towards those goals, Newomics recently announced a new product MnESI-MS platform for clinical diagnostics and drug discovery research, completed the second co-marketing agreement with Thermo Fisher Scientific, and filled several positions in sales and marketing…
…Wang says the next product in the pipeline is a multinozzle emitter array (MEA) technology. “The MEA will increase both the sensitivity and robustness of LC-MS and allow for even higher-throughput experiments. We are thrilled to have new funding to bring this to market in 2021,” he said. Wang and colleagues including co-founder Pan Mao invented the MEA technology at the Lawrence Berkeley National Laboratory.
Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. Its initial M3 emitter product line enables unprecedented gains in sensitivity, throughput, and robustness for liquid chromatography – mass spectrometry (LC-MS). The multinozzle emitter array (MEA) technology, invented at the Lawrence Berkeley National Laboratory, won the 2012 R&D 100 award. Newomics is developing multiomics diagnostic assays for diabetes, Alzheimer’s, and other diseases. It is also developing a microfluidic device to sort, count, and remove cells based on size from blood (the Senescence Chip). The impact of its publications led to a ranking of #71 among the top 100 corporations in the US that dominated research in the natural sciences in 2018.
For more information, view this story.